SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to…

Dianthus Therapeutics, Inc. /DE/ · 144 filed Aug 10, 2026 at 16:34 ET

At the news

NEUTRALIMPACT 2/10

144 filed Aug 10, 2026 at 16:34 ET

Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to sell 5,550 shares of common stock valued at approximately $624,375, with the sale to be executed through a 10b5-1 plan adopted on May 8, 2026. The filing is a routine advance notice of an intended sale under a pre-arranged trading plan and does not indicate a change in the insider's view of the company's prospects. Given the small size of the proposed sale relative to the company's $6.1B market cap, the filing is neutral and low-impact.

  • Officer Simon Read filed a Form 144 to sell 5,550 shares of common stock.
  • The estimated aggregate market value of the proposed sale is $624,375.
  • The sale is to be made pursuant to a 10b5-1 selling plan dated May 8, 2026.
  • The proposed sale represents a very small fraction of the company's $6.1B market capitalization.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access